{"id":"alxn2220","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALXN2220 binds to phosphatidylserine exposed on the surface of apoptotic cells, promoting their recognition and clearance by macrophages and microglia. By enhancing the removal of dying cells and reducing associated neuroinflammatory responses, the drug aims to slow neurodegeneration in conditions characterized by excessive cell death and microglial activation.","oneSentence":"ALXN2220 is a monoclonal antibody that targets phosphatidylserine on apoptotic cells to enhance their clearance and reduce neuroinflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:28.588Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Alzheimer's disease (exploratory)"}]},"trialDetails":[{"nctId":"NCT06183931","phase":"PHASE3","title":"Study of ALXN2220 Versus Placebo in Adults With ATTR-CM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-11","conditions":"Transthyretin Amyloid Cardiomyopathy","enrollment":1181},{"nctId":"NCT07213583","phase":"PHASE2","title":"Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Neurimmune AG","startDate":"2025-08-28","conditions":"Amyloid Transthyretin Cardiomyopathy","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ALXN2220","genericName":"ALXN2220","companyName":"Neurimmune AG","companyId":"neurimmune-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALXN2220 is a monoclonal antibody that targets phosphatidylserine on apoptotic cells to enhance their clearance and reduce neuroinflammation. Used for Parkinson's disease, Alzheimer's disease (exploratory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}